This content is machine translated Chronic lymphocytic leukemia Can CAR T-cell therapy cure CLL? An update Although treatment outcomes have improved, relapsed or refractory chronic lymphocytic leukemia (RRCLL) is still not curable with standard therapies and has a poor prognosis. Long-term data from patients with CLL...…
View Post 27 min This content is machine translated Uveal melanoma Development of a CAR T-cell therapy for uveal melanoma T cells that are endowed with tumor specificity through the expression of a chimeric antigen recept or (CAR) are becoming increasingly important. They are already increasingly being used in adoptive… CME-Test
View Post 27 min This content is machine translated Uveal melanoma Development of a CAR T-cell therapy for uveal melanoma T cells that are endowed with tumor specificity through the expression of a chimeric antigen recept or (CAR) are becoming increasingly important. They are already increasingly being used in adoptive… CME-Test
View Post 2 min This content is machine translated CAR-T cells Focus on innovative cancer therapy CAR-T cells are currently one of the most exciting developments in immunotherapy. It combines immunotherapy, cell therapy and gene therapy and could become a routine treatment in the future.
View Post 10 min This content is machine translated Options in the relapse therapy of multiple myeloma. What comes after the first line? Factors such as pretreatment, age, patient performance, and comorbidities determine relapse therapy in multiple myeloma. Triple combinations with a proteasome inhibitor and/or an IMID are standard. Antibody therapies also play…
